Risankizumab
Brand: Skyrizi
Immunomodulator
IL-23 (p19) monoclonal antibody
Pharmacokinetics
| Half-life | 28 days |
| Clearance Route | reticuloendothelial |
| Active Metabolites | none |
| Notes | Induction: week 0 and 4; Maintenance: every 12 weeks. Linear PK; typical monoclonal antibody elimination. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
URTI, headache, injection site reactions, fatigue
Contraindications:
Active serious infection (TB, invasive fungal)
Precautions:
Evaluate for TB before starting; avoid live vaccines; monitor for infections